Cost-effectiveness of pharmacological anti-obesity treatments: A systematic review

International Journal of Obesity

Volumn 32, Issue 12, 2008, Pages 1752-1763

  Neovius, M ^a   Narbro, K ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Regional Secretariat   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cost utility; Economic evaluation; Orlistat; Rimonabant; Sibutramine

Indexed keywords

ANTIOBESITY AGENT; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIET; ECONOMIC EVALUATION; EXERCISE; HUMAN; OBESITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY MASS INDEX; COST-BENEFIT ANALYSIS; CYCLOBUTANES; EUROPE; HUMANS; LACTONES; OBESITY; PIPERIDINES; PYRAZOLES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 57749204131     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.189     Document Type: Review

References (90)

1. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-1586.
2. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50-71 years old. N Engl J Med 2006; 355: 763-778.
3. Janssen I, Mark AE. Elevated body mass index and mortality risk in the elderly. Obes Rev 2007; 8: 41-59.
4. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355: 779-787.
5. Neovius M, Kark M, Rasmussen F. Association between obesity status in young adulthood and disability pension. Int J Obes (Lond) 2008; 32: 1319-1326.
6. Neovius K, Johansson K, Rossner S, Neovius M. Disability pension, employment and obesity status: a systematic review. Obes Rev 2008; e-pub ahead of print 1 June 2008. PMID: 18518906.
7. Narbro K, Ågren G, Jonsson E, Näslund I, Sjöström L, Peltonen M. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162: 2061-2069.
8. Quesenberry Jr CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466-472.
9. Narbro K, Jonsson E, Larsson B, Waaler H, Wedel H, Sjöström L. Economic consequences of sick-leave and early retirement in obese Swedish women. Int J Obes Relat Metab Disord 1996; 20: 895-903.
10. IOTF. Prevalence of Adult Obesity. Available at http://iotf.org/database/GlobalAdultTableJune07.htm , 2007.
11. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
12. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
13. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006: CD006162.
14. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004: CD004094.
15. Christensen R, Kristensen P, Bartels E, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370 (November 17): 1706-1713.
16. FDA. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant). Advisory Committee - 13 June, 2007. pp 1-88. Available at: http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4306b1-fda
17. NICE. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children, 2006. NICE clinical guideline 43, NHS: London, pp 1-84. Available at: http://www.nice.org. uk/Guidance/CG43
18. NICE. Rimonabant for the treatment of overweight and obese adults, 2008. NICE technology appraisal guidance 144. NHS: London, available at: http://www.nice.org.uk/Guidance/CG43
19. Ara R, Brennan A. The cost-effectiveness of sibutramine in nondiabetic obese patients: evidence from four Western countries. Obes Rev 2007; 8: 363-371.
20. Brennan A, Ara R, Sterz R, Matiba B, Bergemann R. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ 2006; 7: 276-284.
21. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004; 24: 9-19.
22. Malone DC, Raebel MA, Porter JA, Lanty FA, Conner DA, Gay EC et al. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. J Manag Care Pharm 2005; 11: 458-468.
23. Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. Obes Rev 2005; 6: 323-328.
24. Lacey LA, Wolf A, O'Shea D, Erny S, Ruof J. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond) 2005; 29: 975-982.
25. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303-308.
26. Maetzel A, Ruof J, Covington M, Wolf A. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21: 501-512.
27. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1-81.
28. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002; 6: 1-97.
29. Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond) 2005; 29: 517-523.
30. Hampp C, Hartzema AG, Kauf TL. Cost-utility analysis of rimonabant in the treatment of obesity. Value Health 2008; 11: 389-399.
31. Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin 2008; 24: 63-74.
32. van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 2008. [e-pub ahead of print].
33. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 2000; 1: 121-126.
34. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii-iiv, 1-182.
35. Hertzman P. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics 2005; 23: 1007-1020.
36. Edelsberg J, Weycker D, Oster G. Response to Lamotte et al. 'A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients'. Diabetes Care 2002; 25: 1899-1900.
37. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270-279.
38. Kurscheid T, Lauterbach K. The cost implications of obesity for health care and society. Int J Obes Relat Metab Disord 1998; 22 (Suppl 1): S3-S5; discussion S6.
39. Anderson Jr DC. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 2005; 39: 102-109.
40. Lu F, Li S, Le J, Chen G, Cao Y, Qi Yet al. A new method for testing synthetic drugs adulterated in herbal medicines based on infrared spectroscopy. Anal Chim Acta 2007; 589: 200-207.
41. Foxcroft DR, Ludders J. Orlistat for the treatment of obesity, Southampton: Wessex Institute for Health Research and Development, Development and Evaluation Committee Report no. 101, 1999, September.
42. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
43. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-172.
44. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306-313.
45. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61.
46. Hakim Z, Wolf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics 2002; 20: 393-404.
47. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108-1116.
48. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-167.
49. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415-423.
50. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.
51. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-1041.
52. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-1128.
53. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
54. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
55. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
56. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
57. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Part 2): 293-298.
58. Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health 2004; 7: 52-60.
59. Livingston EH, Ko CY. Use of the health and activities limitation index as a measure of quality of life in obesity. Obes Res 2002; 10: 824-832.
60. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2: 121-133.
61. Koopmanschap M. Coping with type II diabetes: the patient's perspective. Diabetologia 2002; 45: S18-S22.
62. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
63. Finer N. Low-calorie diets and sustained weight loss. Obes Res 2001; 9 (Suppl 4): 290S-294S.
64. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579-584.
65. van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metr 2006; 4: 14.
66. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505-512.
67. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-2125.
68. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477-484.
69. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
70. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
71. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group SA. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes 2004; 112: 201-207.
72. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-1339.
73. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
74. Porter JA, Raebel MA, Conner DA, Lanty FA, Vogel EA, Gay EC et al. The long-term outcomes of sibutramine effectiveness on weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004; 10: 369-376.
75. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
76. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
77. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience fromthe RIO-Europe study. Lancet 2005; 365: 1389-1397.
78. Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005; 59: 134-139.
79. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
80. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843-1848.
81. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001; 25: 1047-1056.
82. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-741.
83. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240: 1607-1610.
84. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
85. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care 2001; 7: 875-883.
86. Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2), 2007. Accessed 20 October 2008, available at: http://www.lfn.se/upload/Foretag/ ENG_lfnar2003-eng.pdf
87. Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008; 9: 420-427.
88. Bray GA. Contemporary Diagnosis and Management of Obesity, 2nd edn. Handbooks in Health Care Co.: Newtown, PA, 2003.
89. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191.
90. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5-11.